HeimABBV • NYSE
add
AbbVie Inc
181,14 $
Eftir lokun(0,20%)+0,36
181,50 $
Lokað: 26. nóv., 19:56:10 GMT-5 · USD · NYSE · Lagalegir fyrirvarar
Við síðustu lokun
177,06 $
Dagbil
176,67 $ - 181,65 $
Árabil
137,65 $ - 207,32 $
Markaðsvirði
319,90 ma. USD
Meðalmagn
7,23 m.
V/H-hlutf.
63,20
A/V-hlutfall
3,62%
Aðalkauphöll
NYSE
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 14,46 ma. | 3,83% |
Rekstrarkostnaður | 6,07 ma. | 21,67% |
Nettótekjur | 1,56 ma. | -12,20% |
Hagnaðarhlutfall | 10,80 | -15,43% |
Hagnaður á hvern hlut | 3,00 | 1,69% |
EBITDA | 6,26 ma. | -8,02% |
Virkt skatthlutfall | 24,95% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 7,28 ma. | -45,18% |
Heildareignir | 143,42 ma. | 5,29% |
Heildarskuldir | 137,35 ma. | 10,68% |
Eigið fé alls | 6,07 ma. | — |
Útistandandi hlutabréf | 1,77 ma. | — |
Eiginfjárgengi | 51,92 | — |
Arðsemi eigna | 7,33% | — |
Ávöxtun eigin fjár | 13,48% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 1,56 ma. | -12,20% |
Handbært fé frá rekstri | 5,45 ma. | -28,08% |
Reiðufé frá fjárfestingum | -8,26 ma. | -2.137,40% |
Reiðufé frá fjármögnun | -3,07 ma. | -15,45% |
Breyting á handbæru fé | -5,87 ma. | -229,70% |
Frjálst peningaflæði | 5,50 ma. | -26,01% |
Um
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, and rank 89 on the 2024 list. The company's primary product is Humira, administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.
It developed Skyrizi, an interleukin-23 inhibitor also used to treat autoimmune diseases. Its other major products include Botox, Imbruvica to treat cancer, Rinvoq to treat arthritis, Venclexta to treat leukemia and lymphoma, Vraylar to treat schizophrenia and bipolar disorder, and Mavyret to treat Hepatitis C. The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis.
In 2023, Humira began facing competition from a biosimilar developed by Amgen. Wikipedia
Stofnsett
1. jan. 2013
Höfuðstöðvar
Vefsvæði
Starfsfólk
50.000
